Online inquiry

IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ15736MR)

This product GTTS-WQ15736MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets SEMA4D gene. The antibody can be applied in Multiple sclerosis (MS) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001142287.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 10507
UniProt ID Q92854
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SEMA4D, VX-15(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ15736MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ721MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA A-623
GTTS-WQ5973MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CLLB8
GTTS-WQ7571MR IVTScrip™ mRNA-Anti-CSF3R, G-CSF(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA G-CSF
GTTS-WQ3090MR IVTScrip™ mRNA-Anti-FASLG, APG-101(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA APG-101
GTTS-WQ14757MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA SGN-35
GTTS-WQ11267MR IVTScrip™ mRNA-Anti-hly, MEDI4893(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI4893
GTTS-WQ14493MR IVTScrip™ mRNA-Anti-CNR1, RYI-018(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA RYI-018
GTTS-WQ4564MR IVTScrip™ mRNA-Anti-CXCR4, BMS-936564(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BMS-936564
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW